Company: TELO
Filing Date: 2025-01-07
Form Type: 8-K
Source: 0001493152-25-001112
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-01-07
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (a rare
genetic disorder causing rapid aging)

Telomir
Pharmaceuticals, Inc. (Nasdaq: TELO), an emerging leader in age-reversal science, announced significant findings from a preclinical study
focusing on progeria, a rare genetic condition that causes children to age much faster than normal. Progeria leads to health issues commonly
associated with aging, such as growth problems, stiff joints, heart disease, and premature death, often in the early teens.

The
study was conducted in nematodes (C. elegans) with a mutation in the wrn-1 gene, which is similar to a gene in humans linked to Werner
Syndrome, a form of Progeria. Nematodes with this mutation had much shorter lifespans compared to normal ones. However, Telomir-1 was
able to restore their lifespan to near-normal levels. These findings suggest that Telomir-1 could potentially help address the cellular
issues that cause rapid aging and related health problems.

Cautionary
Note Regarding Forward Looking Statements

This
Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as
“may,” “will,” “expect,” “intend,” “plans,” “anticipate,” “believe,”
“estimate,” “continue” and similar words. Such statements are only predictions and actual events or results may
differ materially from those anticipated in these forward-looking statements. You should not place undue reliance on any forward-looking
statements. In this report, such forward-looking statements relate to the anticipated benefits to the Company of the preclinical study
results disclosed herein, the future of the Company’s development and testing of Telomir-1, and other forward-looking matters related
to the Company’s plans as described herein. Readers are cautioned that actual future results related to these matters may deviate
materially and adversely from the forward-looking statements contained herein. The Company does not assume any obligation to update forward-looking
statements as circumstances change, except as required by securities laws.

SIGNATURES

Pursuant
to the